Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00003563 | Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases | PHASE3 | COMPLETED | 430 | — | — | Aug 1, 1998 | Jun 1, 2005 | Oct 31, 2013 | 35 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| WBRT | EXPERIMENTAL | 3 Gy of WBRT daily for a total of 10 days |
| MGd | EXPERIMENTAL | IV does of 5.0 mg/kg MGd plus WBRT |
| Name | Type | Description |
|---|---|---|
| WBRT | RADIATION | 3 GY of WBRT daily for a total of 10 days |
| MGd | DRUG | 5.0 mg /kg MGd plus WBRT |
DISEASE CHARACTERISTICS: Histologically proven solid tumor with parenchymal brain metastasis Solitary metastasis eligible only if refused surgery or surgical resection deemed inappropriate No leptomeningeal metastases or subarachnoid spread of tumor No small cell lung cancer, germ cell tumors, lymph...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |